Αρχική World News PICOS Score May Help in Identification of Patients with Brain Metastasis at...

PICOS Score May Help in Identification of Patients with Brain Metastasis at High Risk for VTEs

In a large series of patients with brain metastasis, venous thromboembolic events (VTEs) were found in 12% of cases. The study team identified thrombogenicity of primary tumour, immobilisation, chemotherapy, obesity, and steroid use that are factors independently associated with VTEs and making components of the PICOS score. Fabian Wolpert of the Department of Neurology, University Hospital Zuirich in Zurich, Switzerland and colleagues reported in the European Journal of Cancer that the PICOS score is superior to established risk models for VTE risk estimation in cancer patients.

The study team reported in background that VTEs represent significant complications in patients with systemic malignancies. In patients with brain metastasis risk of thrombosis is poorly defined. Furthermore, available risk calculation scores are not validated in this population.

The authors identified 811 patients with brain metastasis. They retrospectively reviewed electronic charts for the occurrence of VTEs. Furthermore, they reviewed risk factors. Risk factors were tested in univariate and multivariate analyses and finally integrated in a score model for risk estimation. For validation phase, an independent cohort of 346 patients with brain metastasis was available.

From 811 patients included in the analysis, VTEs were documented in 97 patients (12.0%). The study team confirmed that next parameters are independently associated with VTEs: primary tumours with high thrombogenicity (p = 0.02, hazard ratio [HR] 1.7, 95% confidence interval [CI] 1.1–2.8), dexamethasone (p = 0.011, HR 2.27, 95% CI 1.5–4.5), chemotherapy (p = 0.005, HR 3.4, 95% CI 1.6–7.5), body mass index > 35 kg/m 2 (p = 0.002, HR 3.4, 95% CI 1.6–7.5) and immobilisation (p = 0.003, HR 2.4, 95% CI 1.3–4.3).

The authors derived a score model for VTE risk estimation called PICOS which is based on the thrombogenicity of primary tumour, immobilisation, chemotherapy, obesity, steroid use with possible score of 0 to 7 points.

They ran receiver-operating characteristic curve analysis which demonstrated its prognostic accuracy (area under the curve [AUC] 0.71, 95% CI 0.64–0.77). Its value for the evaluation of VTE risk was superior to that of other scores such as the Khorana (AUC 0.51) or CONKO (AUC 0.52) scores. The potential value of the PICOS score was confirmed in the validation cohort (AUC 0.72, 95% CI 0.63–0.82).

The authors concluded that the PICOS score may become a helpful tool to identify patients with brain metastasis who are at high risk for VTEs. It may be useful for stratification in controlled studies.


Wolpert F, Berghoff AS, Grossenbacher B, et al. Venous thromboembolic events in patients with brain metastases: the PICOS score. European Journal of Cancer 2020; 134:P75-85. DOI: https://doi.org/10.1016/j.ejca.2020.04.018



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...